Hosted on MSN20d
Pharmacy Benefit Managers Not Thrilled With FTC Report Finding Pharmacy Benefit Managers Raise Drug PricesThe pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen.
Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...
The Federal Trade Commission has released its second report digging into how the business practices of pharmacy benefit managers could be inflating drug costs in the U.S., in the latest and likely ...
The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...
WASHINGTON, Jan 14 (Reuters) - The nation's three largest pharmacy ... FTC spokesperson told reporters in a press briefing, adding that the figure was "probably an underestimate." Pharmacy benefit ...
A new FTC report found that pharmacy benefit managers have inflated the price of life-saving generic prescription drugs, ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...
The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback